NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Neurocrine is a biopharmaceutical company focused on the discovery and development of novel therapeutics for neurologic and endocrine diseases. The company has no marketed products and generates revenue primarily through strategic collaborations and research grants. Its lead clinical candidate is indiplon (for insomnia), which was in Phase III trials as of year-end. The company maintains a pipeline of 16 programs, seven of which are in clinical development.

Key Financial Metrics

Note: The company does not report gross margins or operating margins in the traditional sense as it has no product sales revenue. Revenue is derived from sponsored research, milestones, and license fees.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by approximately 56% (from $41.2 million to $18.0 million). This was primarily due to the absence of $21.0 million in milestone payments recognized in 2001 under collaborations with Taisho and GlaxoSmithKline (GSK).
• Increased Operating Loss: Net loss more than doubled to $94.5 million from $36.9 million. This increase was driven by a 47% rise in R&D expenses ($108.9 million vs. $74.3 million) as the company expanded clinical trials, particularly for the indiplon Phase III program, and increased scientific personnel.
• Cash Position: Cash and short-term investments decreased by approximately $75.3 million to $244.7 million, reflecting the funding of expanded clinical development activities. However, this balance excludes a $100 million upfront payment from Pfizer expected in early 2003.

Guidance, Outlook, and Risks

Strategic Developments

• Pfizer Collaboration: In December 2002, Neurocrine entered an exclusive worldwide collaboration with Pfizer for indiplon. Neurocrine expects to receive a $100 million upfront payment in Q1 2003 and up to $300 million in milestone payments. Pfizer will fund the majority of future development costs and commercialization.
• Indiplon Status: Phase III trials for insomnia are ongoing. The company plans to file a New Drug Application (NDA) in late 2003 or early 2004.
• Other Programs: Development continues on NBI-5788 (Multiple Sclerosis), NBI-6024 (Type 1 Diabetes), and CRF antagonists (Anxiety/Depression) in collaboration with GSK.

Outlook and Risks

• Profitability: The company expects to incur substantial losses and negative operating cash flows for the foreseeable future. It does not expect to achieve profitability in 2003.
• Liquidity: Management believes existing capital resources, interest income, and future collaboration payments will satisfy funding requirements for at least the next 12 months.
• Key Risks:
  • Failure of clinical trials to demonstrate safety or efficacy.
  • Dependence on strategic partners (Pfizer, GSK, etc.) for funding and commercialization.
  • Regulatory delays or rejection of NDAs.
  • Potential need for additional equity or debt financing if milestones are not met or trials are delayed.

Investor Verification Checklist

• Pfizer Payment Timing: Verify the receipt of the $100 million upfront payment from Pfizer in Q1 2003 as anticipated.
• Indiplon Trial Data: Monitor the release of Phase III clinical trial results for indiplon to assess the likelihood of FDA approval.
• Burn Rate: Track quarterly R&D expenses to ensure they align with the projected runway of 12+ months of liquidity.
• Collaboration Milestones: Review progress on GSK and Taisho collaborations to determine if future milestone revenues are achievable.
• Patent Status: Confirm the status of patent applications for indiplon and other key candidates to ensure protection against generic competition.